Skip to main content
Erschienen in: Clinical and Experimental Nephrology 1/2008

01.02.2008 | Original Article

Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review

verfasst von: Marie D. Philipneri, Lisa A. Rocca Rey, Mark A. Schnitzler, Kevin C. Abbott, Daniel C. Brennan, Steven K. Takemoto, Paula M. Buchanan, Thomas E. Burroughs, Lisa M. Willoughby, Krista L. Lentine

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Clinical practice guidelines for management of chronic kidney disease (CKD) have been developed within the Kidney Disease Outcomes Quality Initiative (K/DOQI). Adherence patterns may identify focus areas for quality improvement.

Methods

We retrospectively studied contemporary CKD care patterns within a private health system in the United States, and systematically reviewed literature of reported practices internationally. Five hundred and nineteen patients with moderate CKD (estimated GFR 30–59 ml/min) using healthcare benefits in 2002–2005 were identified from administrative insurance records. Thirty-three relevant publications in 2000–2006 describing care in 77,588 CKD patients were reviewed. Baseline demographic traits and provider specialty were considered as correlates of delivered care. Testing consistent with K/DOQI guidelines and prevalence of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) medication prescriptions were ascertained from billing claims. Care descriptions in the literature sample were based on medical charts, electronic records and/or claims.

Results

KDOQI-consistent measurements of parathyroid hormone (7.1 vs. 0.6%, P = 0.0002), phosphorus (38.2 vs. 1.9%, P < 0.0001) and quantified urinary protein (23.8 vs. 9.4%, P = 0.008) were more common among CKD patients with versus without nephrology referral in the administrative data. Nephrology referral correlated with increased likelihood of testing for parathyroid hormone and phosphorus after adjustment for baseline patient factors. Use of ACEi/ARB medications was more common among patients with nephrology contact (50.0 vs. 30.0%; P = 0.008) but appeared largely driven by higher comorbidity burden. The literature review demonstrated similar practice patterns.

Conclusions

Delivery of CKD care may be monitored by administrative data. There is opportunity for improvement in CKD guideline adherence in practice.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1–12.CrossRefPubMed Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1–12.CrossRefPubMed
3.
Zurück zum Zitat Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Inter Med. 2005;142(5):342–51.CrossRef Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Inter Med. 2005;142(5):342–51.CrossRef
4.
Zurück zum Zitat Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359–64.CrossRefPubMed Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359–64.CrossRefPubMed
5.
Zurück zum Zitat Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Inter Med. 2003;139(4):244–52.CrossRef Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Inter Med. 2003;139(4):244–52.CrossRef
6.
Zurück zum Zitat Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001;12(7):1501–7.PubMed Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001;12(7):1501–7.PubMed
7.
Zurück zum Zitat Winkelmayer WC, Levin R, Avorn J. The nephrologist’s role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. Kidney Int. 2003;63(5):1836–42.CrossRefPubMed Winkelmayer WC, Levin R, Avorn J. The nephrologist’s role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. Kidney Int. 2003;63(5):1836–42.CrossRefPubMed
8.
Zurück zum Zitat Lafayette RA, Lai G. Examining chronic kidney disease management in a single center. Clin Nephrol. 2004;62(4):260–6.CrossRefPubMed Lafayette RA, Lai G. Examining chronic kidney disease management in a single center. Clin Nephrol. 2004;62(4):260–6.CrossRefPubMed
9.
Zurück zum Zitat Kausz AT, Guo H, Pereira BJ, Collins AJ, Gilbertson DT. General medical care among patients with chronic kidney disease: opportunities for improving outcomes. J Am Soc Nephrol. 2005;16(10):3092–101.CrossRefPubMed Kausz AT, Guo H, Pereira BJ, Collins AJ, Gilbertson DT. General medical care among patients with chronic kidney disease: opportunities for improving outcomes. J Am Soc Nephrol. 2005;16(10):3092–101.CrossRefPubMed
10.
Zurück zum Zitat Murray BM, Malireddi K, Vavilala V. Delivery of predialysis care in an academic referral nephrology practice. Ren Fail. 2005;27(5):571–80.CrossRefPubMed Murray BM, Malireddi K, Vavilala V. Delivery of predialysis care in an academic referral nephrology practice. Ren Fail. 2005;27(5):571–80.CrossRefPubMed
11.
Zurück zum Zitat National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
12.
Zurück zum Zitat Avorn J, Bohn RL, Levy E, Levin R, Owen WF Jr, Winkelmayer WC, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Inter Med. 2002;162(17):2002–6.CrossRef Avorn J, Bohn RL, Levy E, Levin R, Owen WF Jr, Winkelmayer WC, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Inter Med. 2002;162(17):2002–6.CrossRef
13.
Zurück zum Zitat Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Inter Med. 2002;137(6):479–86.CrossRef Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Inter Med. 2002;137(6):479–86.CrossRef
14.
Zurück zum Zitat Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31(3):398–417.CrossRefPubMed Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31(3):398–417.CrossRefPubMed
15.
Zurück zum Zitat De Nicola L, Minutolo R, Chiodini P, Zoccali C, Castellino P, Donadio C, et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int. 2006;69(3):538–45.CrossRefPubMed De Nicola L, Minutolo R, Chiodini P, Zoccali C, Castellino P, Donadio C, et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int. 2006;69(3):538–45.CrossRefPubMed
16.
Zurück zum Zitat Israni A, Korzelius C, Townsend R, Mesler D. Management of chronic kidney disease in an academic primary care clinic. Am J Nephrol. 2003;23(1):47–54.CrossRefPubMed Israni A, Korzelius C, Townsend R, Mesler D. Management of chronic kidney disease in an academic primary care clinic. Am J Nephrol. 2003;23(1):47–54.CrossRefPubMed
17.
18.
Zurück zum Zitat Saelen MG, Prosch LK, Gudmundsdottir H, Dyrbekk D, Helge Hunderi O, Arnesen E, et al. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function. Blood Press. 2005;14(3):170–6.CrossRefPubMed Saelen MG, Prosch LK, Gudmundsdottir H, Dyrbekk D, Helge Hunderi O, Arnesen E, et al. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function. Blood Press. 2005;14(3):170–6.CrossRefPubMed
19.
Zurück zum Zitat National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201.
20.
Zurück zum Zitat Kidney Disease Outcomes Quality Initiative G. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 Suppl 3):I–IV. Kidney Disease Outcomes Quality Initiative G. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 Suppl 3):I–IV.
21.
Zurück zum Zitat de Lusignan S, Chan T, Stevens P, O’Donoghue D, Hague N, Dzregah B, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22(3):234–41.CrossRefPubMed de Lusignan S, Chan T, Stevens P, O’Donoghue D, Hague N, Dzregah B, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22(3):234–41.CrossRefPubMed
22.
Zurück zum Zitat Stevens LA, Fares G, Fleming J, Martin D, Murthy K, Qiu J, et al. Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2439–48.CrossRefPubMed Stevens LA, Fares G, Fleming J, Martin D, Murthy K, Qiu J, et al. Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2439–48.CrossRefPubMed
23.
Zurück zum Zitat Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. (see comment). Am J Hypertens. 2001;14(12):1219–25.CrossRefPubMed Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. (see comment). Am J Hypertens. 2001;14(12):1219–25.CrossRefPubMed
24.
Zurück zum Zitat Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis. 2001;38(6):1398–407.CrossRefPubMed Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis. 2001;38(6):1398–407.CrossRefPubMed
25.
Zurück zum Zitat Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12(8):1713–20.PubMed Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12(8):1713–20.PubMed
26.
Zurück zum Zitat Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37(3):484–9.CrossRefPubMed Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37(3):484–9.CrossRefPubMed
27.
Zurück zum Zitat Cleveland DR, Jindal KK, Hirsch DJ, Kiberd BA. Quality of prereferral care in patients with chronic renal insufficiency. Am J Kidney Dis. 2002;40(1):30–6.CrossRefPubMed Cleveland DR, Jindal KK, Hirsch DJ, Kiberd BA. Quality of prereferral care in patients with chronic renal insufficiency. Am J Kidney Dis. 2002;40(1):30–6.CrossRefPubMed
28.
Zurück zum Zitat De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13(11):2762–9.CrossRefPubMed De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13(11):2762–9.CrossRefPubMed
29.
Zurück zum Zitat Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62(1):229–36.CrossRefPubMed Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62(1):229–36.CrossRefPubMed
30.
Zurück zum Zitat London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis. 2002;40(3):539–48.CrossRefPubMed London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis. 2002;40(3):539–48.CrossRefPubMed
31.
Zurück zum Zitat Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant. 2002;17(8):1426–33.CrossRefPubMed Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant. 2002;17(8):1426–33.CrossRefPubMed
32.
Zurück zum Zitat London R, Solis A, Goldberg GA, Wade S, Chan WW. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population. J Manage Care Pharm. 2003;9(3):248–55. London R, Solis A, Goldberg GA, Wade S, Chan WW. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population. J Manage Care Pharm. 2003;9(3):248–55.
33.
Zurück zum Zitat Perlman RL, Kiser M, Finkelstein F, Eisele G, Roys E, Liu L, et al. The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure. Semin Dial. 2003;16(6):418–23.CrossRefPubMed Perlman RL, Kiser M, Finkelstein F, Eisele G, Roys E, Liu L, et al. The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure. Semin Dial. 2003;16(6):418–23.CrossRefPubMed
34.
Zurück zum Zitat Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am College Cardiol. 2004;44(8):1587–92.CrossRef Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am College Cardiol. 2004;44(8):1587–92.CrossRef
35.
Zurück zum Zitat McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. (see comment). Circulation. 2004;109(8):1004–9.CrossRefPubMed McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. (see comment). Circulation. 2004;109(8):1004–9.CrossRefPubMed
36.
Zurück zum Zitat Rosen AB, Karter AJ, Liu JY, Selby JV, Schneider EC. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Inter Med. 2004;19(6):669–75.CrossRef Rosen AB, Karter AJ, Liu JY, Selby JV, Schneider EC. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Inter Med. 2004;19(6):669–75.CrossRef
37.
Zurück zum Zitat So WY, Ozaki R, Chan NN, Tong PC, Ho CS, Lam CW, et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension. 2004;44(3):294–9.CrossRefPubMed So WY, Ozaki R, Chan NN, Tong PC, Ho CS, Lam CW, et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension. 2004;44(3):294–9.CrossRefPubMed
38.
Zurück zum Zitat Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20(6):1110–5.CrossRefPubMed Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20(6):1110–5.CrossRefPubMed
39.
Zurück zum Zitat De Nicola L, Minutolo R, Zamboli P, Cestaro R, Marzano L, Giannattasio P, et al. Italian audit on therapy of hypertension in chronic kidney disease: the TABLE-CKD study. Semin Nephrol. 2005;25(6):425–30.CrossRefPubMed De Nicola L, Minutolo R, Zamboli P, Cestaro R, Marzano L, Giannattasio P, et al. Italian audit on therapy of hypertension in chronic kidney disease: the TABLE-CKD study. Semin Nephrol. 2005;25(6):425–30.CrossRefPubMed
40.
Zurück zum Zitat Leehey DJ, Kramer HJ, Daoud TM, Chatha MP, Isreb MA. Progression of kidney disease in type 2 diabetes—beyond blood pressure control: an observational study. BMC Nephrol. 2005;6(1):8.CrossRefPubMedPubMedCentral Leehey DJ, Kramer HJ, Daoud TM, Chatha MP, Isreb MA. Progression of kidney disease in type 2 diabetes—beyond blood pressure control: an observational study. BMC Nephrol. 2005;6(1):8.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Minutolo R, De Nicola L, Zamboli P, Chiodini P, Signoriello G, Toderico C, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46(1):18–25.CrossRefPubMed Minutolo R, De Nicola L, Zamboli P, Chiodini P, Signoriello G, Toderico C, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46(1):18–25.CrossRefPubMed
42.
Zurück zum Zitat Thanamayooran S, Rose C, Hirsch DJ. Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guideline targets. Nephrol Dial Transplant. 2005;20(11):2385–93.CrossRefPubMed Thanamayooran S, Rose C, Hirsch DJ. Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guideline targets. Nephrol Dial Transplant. 2005;20(11):2385–93.CrossRefPubMed
43.
Zurück zum Zitat Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46(6):1080–7.CrossRefPubMed Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46(6):1080–7.CrossRefPubMed
44.
Zurück zum Zitat Jayapaul MK, Messersmith R, Bennett-Jones DN, Mead PA, Large DM. The joint diabetic-renal clinic in clinical practice: 10 years of data from a District General Hospital. Qjm. 2006;99(3):153–60.CrossRefPubMed Jayapaul MK, Messersmith R, Bennett-Jones DN, Mead PA, Large DM. The joint diabetic-renal clinic in clinical practice: 10 years of data from a District General Hospital. Qjm. 2006;99(3):153–60.CrossRefPubMed
45.
Zurück zum Zitat Jones C, Roderick P, Harris S, Rogerson M. An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD. Am J Kidney Dis. 2006;47(1):103–14.CrossRefPubMed Jones C, Roderick P, Harris S, Rogerson M. An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD. Am J Kidney Dis. 2006;47(1):103–14.CrossRefPubMed
46.
Zurück zum Zitat Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Inter Med. 2006;166(17):1884–91.CrossRef Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Inter Med. 2006;166(17):1884–91.CrossRef
47.
Zurück zum Zitat Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21:2133–43.CrossRefPubMed Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21:2133–43.CrossRefPubMed
49.
Zurück zum Zitat Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification, referral of patients with progressive CKD: a national study. Am J Kidney Dis. 2006;48(2):192–204.CrossRefPubMed Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification, referral of patients with progressive CKD: a national study. Am J Kidney Dis. 2006;48(2):192–204.CrossRefPubMed
50.
Zurück zum Zitat Lea JP, McClellan WM, Melcher C, Gladstone E, Hostetter T. CKD risk factors reported by primary care physicians: do guidelines make a difference? Am J Kidney Dis. 2006;47(1):72–7.CrossRefPubMed Lea JP, McClellan WM, Melcher C, Gladstone E, Hostetter T. CKD risk factors reported by primary care physicians: do guidelines make a difference? Am J Kidney Dis. 2006;47(1):72–7.CrossRefPubMed
51.
Zurück zum Zitat Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Inter Med. 2005;165(14):1637–42.CrossRef Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Inter Med. 2005;165(14):1637–42.CrossRef
52.
Zurück zum Zitat Gilmer TP, O’Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28(1):59–64.CrossRefPubMed Gilmer TP, O’Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28(1):59–64.CrossRefPubMed
53.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351(13):1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351(13):1296–305.CrossRefPubMed
54.
Zurück zum Zitat Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Inter Med. 2002;162(20):2269–76.CrossRef Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Inter Med. 2002;162(20):2269–76.CrossRef
55.
Zurück zum Zitat Stirnemann PM, Takemoto SK, Schnitzler MA, Brennan DC, Abbott KC, Salvalaggio P, et al. Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey. J Am Soc Nephrol. 2006;17(8):2299–306.CrossRefPubMed Stirnemann PM, Takemoto SK, Schnitzler MA, Brennan DC, Abbott KC, Salvalaggio P, et al. Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey. J Am Soc Nephrol. 2006;17(8):2299–306.CrossRefPubMed
Metadaten
Titel
Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review
verfasst von
Marie D. Philipneri
Lisa A. Rocca Rey
Mark A. Schnitzler
Kevin C. Abbott
Daniel C. Brennan
Steven K. Takemoto
Paula M. Buchanan
Thomas E. Burroughs
Lisa M. Willoughby
Krista L. Lentine
Publikationsdatum
01.02.2008
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 1/2008
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-007-0016-3

Weitere Artikel der Ausgabe 1/2008

Clinical and Experimental Nephrology 1/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.